Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
BMC Cancer|February 28, 2019
Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinomaKei Namba, Shuta Tomida, Takehiro Matsubara, et al.Journal of Cachexia, Sarcopenia and Muscle|April 14, 2026
Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase DataShiho Ueta, Takahiro Niimura, Mitsuhiro Goda, et al.Eclinicalmedicine|August 12, 2025
Global trends in mortality related to pulmonary embolism: an epidemiological analysis of data from the World Health Organization mortality database from 2001 to 2023Hideharu Hagiya, Ko Harada, Yoshito Nishimura, et al.Molecular and Cellular Biochemistry|December 26, 2022
Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinomaJun Matsumoto, Anzu Nishimoto, Shogo Watari, et al.Anticancer Research|April 7, 2019
Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung CancerEisuke Kurihara, Kazuhiko Shien, Hidejiro Torigoe, et al.Cancer Science|July 24, 2022
Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblastKosuke Ochi, Ken Suzawa, Yin Min Thu, et al.Anticancer Research|May 6, 2020
Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF MutationShunsaku Miyauchi, Kazuhiko Shien, Tatsuaki Takeda, et al.Biochemical and Biophysical Research Communications|August 2, 2020
Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancerKosuke Ochi, Ken Suzawa, Shuta Tomida, et al.International Journal of Molecular Sciences|December 10, 2021
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance DevelopmentMiwa Fujihara, Tadahiko Shien, Kazuhiko Shien, et al.Plos One|February 4, 2017
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancerTatsuaki Takeda, Hiromasa Yamamoto, Hirotaka Kanzaki, et al.Pageof 3